No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.
www.bioextrax.comNo one on the platform currently holds BIOEX.ST.
No tracked institution reports a position in BIOEX.ST as of their last filing.
No one on the platform has traded BIOEX.ST yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 47.0% | 103.3% | ||||
| Profit Margin % | -2338.8% | -3059.3% | ||||
| Free Cash Flow Margin % | -3460.8% | -3587.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $804000 | -23.7% | $-0.37 | $-0.37–$-0.37 | — | 1 |
| 2027 | $8M | +859.7% | $-0.26 | $-0.26–$-0.26 | — | 1 |
| 2028 | $35M | +353.3% | $0.02 | $0.02–$0.02 | — | 1 |
| 2029 | $81M | +132.2% | $0.48 | $0.48–$0.48 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $-0.09 | $-0.10 | -11.1% |
| 2026-05-20 | $-0.10 | $-0.09 | +10.0% |
| 2026-02-19 | $-0.11 | $-0.11 | -0.5% |
| 2025-11-21 | $-0.11 | $-0.11 | +1.1% |
| -1.25% |
| $103M |
| — |
| HEXI.STHexicon AB (publ) | $0.11 | -3.08% | $40M | — |
| LEVEL.STNordic LEVEL Group AB (publ.) | $0.31 | -2.52% | $67M | — |
Source: Financial Modeling Prep · peers by sector/industry